Vezina S - Search Results

1

Tolerability is more important than simplicity for treatment durability.

Trottier B, Machouf N, Huchet E, Lavoie S, Vezina S, Boissonnault M, Charest L, Munoz M, Legault D, Longpré D, Thomas R. Trottier B, et al. Among authors: vezina s. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19765. doi: 10.7448/IAS.17.4.19765. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397509 Free PMC article.

2

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study.

Trottier B, Longpré D, Dion H, Vezina S, Lavoie S, Galanakis C, Machouf N, Thomas R. Trottier B, et al. Among authors: vezina s. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19815. doi: 10.7448/IAS.17.4.19815. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397559 Free PMC article.

3

Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy.

Trottier B, Machouf N, Thomas R, Gallant S, Longpré D, Vézina S, Boissonnault M, Lavoie S, Legault D, Dion H, Nguyen VK. Trottier B, et al. Among authors: vezina s. HIV Clin Trials. 2012 Nov-Dec;13(6):335-42. doi: 10.1310/hct1306-335. HIV Clin Trials. 2012. PMID: 23195671

4

Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.

Thomas R, Galanakis C, Vézina S, Longpré D, Boissonnault M, Huchet E, Charest L, Murphy D, Trottier B, Machouf N. Thomas R, et al. Among authors: vezina s. PLoS One. 2015 Nov 11;10(11):e0142534. doi: 10.1371/journal.pone.0142534. eCollection 2015. PLoS One. 2015. PMID: 26559816 Free PMC article.

5

Transmission networks of drug resistance acquired in primary/early stage HIV infection.

Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA; Montreal PHI Cohort and HIV Prevention Study Groups. Brenner BG, et al. AIDS. 2008 Nov 30;22(18):2509-15. doi: 10.1097/QAD.0b013e3283121c90. AIDS. 2008. PMID: 19005274 Free PMC article.

6

Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.

Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, Cox J, Tremblay C, Lu W, Singer J, Li T, Routy JP; Montreal Primary HIV Infection Study Group; Vézina S, Charest L, Milne M, Huchet E, Lavoie S, Friedman J, Duchastel M, Villielm F, Côté P, Potter M, Lessard B, Charron MA, Dufresne S, Turgeon ME, Rouleau D, Labrecque L, Fortin C, de Pokomandy A, Hal-Gagné V, Munoz M, Deligne B, Martel-Laferrière V, Gilmore N, Fletcher M, Szabo J. Cao W, et al. Among authors: vezina s. Clin Infect Dis. 2016 Jan 15;62(2):250-257. doi: 10.1093/cid/civ809. Epub 2015 Sep 8. Clin Infect Dis. 2016. PMID: 26349551 Free PMC article.

7

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054).

Trottier B, Galanakis C, Longpré D, Dion H, Vézina S, Lavoie S, Boissonnault M, Costiniuk C, Jenabian MA, Machouf N, Thomas R. Trottier B, et al. Among authors: vezina s. HIV Clin Trials. 2015 May-Jun;16(3):111-6. doi: 10.1179/1528433614Z.0000000015. HIV Clin Trials. 2015. PMID: 25997535

8

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

Oliveira M, Ibanescu RI, Anstett K, Mésplède T, Routy JP, Robbins MA, Brenner BG; Montreal Primary HIV (PHI) Cohort Study Group. Oliveira M, et al. Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3. Retrovirology. 2018. PMID: 30119633 Free PMC article.

9

Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec.

Brenner BG, Roger M, Stephens D, Moisi D, Hardy I, Weinberg J, Turgel R, Charest H, Koopman J, Wainberg MA; Montreal PHI Cohort Study Group. Brenner BG, et al. J Infect Dis. 2011 Oct 1;204(7):1115-9. doi: 10.1093/infdis/jir468. J Infect Dis. 2011. PMID: 21881127 Free PMC article.

10

Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors. Kamya P, et al. J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6. J Virol. 2011. PMID: 21471235 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page